There is increasing global demand for life-changing CAR T-cell therapies. Existing manufacturing processes can’t keep up: they’re labour-intensive and costs are prohibitive.

By automating the manufacture of cutting-edge CAR T-cell therapies, we can accelerate the pace from clinical trial to commercial reality without compromising efficacy, safety and quality.

Alongside our partners, we combine advanced manufacturing technologies with world-class clinical models of care to reach launch faster.

Funds raised will be used to:

• Complete the current CAR T-cell clinical trial with our partner, the Malaghan Institute of Medical Research

• Continue development of our closed manufacturing platform

• Build New Zealand’s first self-contained CAR T-cell manufacturing facility